For many technology and pharmaceutical firms…
A. a large portion of their value to an acquirer might relate to in-process research and development (IPR&D).
B. in-process research and development (IPR&D) acquired in a business combination that meets the separability criterion as an asset is recognized and measured initially at fair value.
C. the firm that developed the in-process research and development (IPR&D) expensed the costs as they were incurred.
D. all of the above
E. none of the above
Correct answer is D ( i.e. All of the above ).
Explanation:
In respect of Technology and pharmaceutical firms usally a large portion of their value to an acquirer might relate to in-process research and development (IPR&D). Their in-process research and development (IPR&D) acquired in a business combination that meets the separability criterion as an asset is recognized and measured initially at fair value. Firm that developed the in-process research and development (IPR&D) expensed the costs as they were incurred.
Get Answers For Free
Most questions answered within 1 hours.